STOCK TITAN

Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

Cytek Biosciences (Nasdaq: CTKB) announced it has relocated its European headquarters to a new facility in Amsterdam's Life Sciences District effective Oct 15, 2025. The site expands Cytek's European footprint by more than 40% and houses offices, an enlarged warehouse, and a dedicated customer service and training center with a fully functional lab for hands-on training on Cytek's Full Spectrum Profiling™ (FSP®) technology.

The company cited strong reagent-business performance as a key driver and has transitioned warehouse operations in-house to improve quality control, operational agility, and turnaround times across EMEA.

Cytek Biosciences (Nasdaq: CTKB) ha annunciato di aver trasferito la sede europea in una nuova struttura nel Life Sciences District di Amsterdam con effetto dal 15 ottobre 2025. Il sito amplia la presenza europea di Cytek di più di 40% e ospita uffici, un magazzino ampliato e un centro dedicato al servizio clienti e alla formazione con un laboratorio pienamente funzionale per la formazione pratica sulla tecnologia Full Spectrum Profiling™ (FSP®) di Cytek.

L'azienda ha indicato una forte performance del business dei reagenti come motore chiave ed ha internalizzato le operazioni di magazzino per migliorare il controllo qualità, l'agilità operativa e i tempi di turnaround in tutta la regione EMEA.

Cytek Biosciences (Nasdaq: CTKB) anunció que ha trasladado su sede europea a una nueva instalación en el Life Sciences District de Ámsterdam, con efecto a partir del 15 de octubre de 2025. El sitio amplía la presencia europea de Cytek en más de 40% y alberga oficinas, un almacén ampliado y un centro dedicado de atención al cliente y formación con un laboratorio totalmente funcional para capacitación práctica en la tecnología Full Spectrum Profiling™ (FSP®) de Cytek.

La empresa señaló un sólido rendimiento del negocio de reactivos como motor clave y ha trasladado las operaciones de almacén internamente para mejorar el control de calidad, la agilidad operativa y los tiempos de respuesta en la región EMEA.

Cytek Biosciences (나스닥: CTKB)는 2025년 10월 15일부터 암스테르담의 Life Sciences District에 있는 새로운 시설로 유럽 본사를 이전했다고 발표했습니다. 이 부지는 Cytek의 유럽 입지를 40% 이상 확장하고, 사무실, 확장된 창고 및 Cytek의 Full Spectrum Profiling™ (FSP®) 기술에 대한 현장 교육이 가능한 헌신적인 고객 서비스 및 교육 센터를 포함합니다.

회사는 시약 사업의 강력한 실적을 주요 동력으로 지목했으며 품질 관리, 운영 민첩성 및 EMEA 전역의 처리 시간을 개선하기 위해 창고 운영을 내부로 이전했습니다.

Cytek Biosciences (Nasdaq: CTKB) a annoncé avoir déplacé son siège européen vers une nouvelle installation dans le quartier Life Sciences d'Amsterdam, à compter du 15 octobre 2025. Le site étend l'empreinte européenne de Cytek de plus de 40% et abrite des bureaux, un entrepôt élargi et un centre dédié au service client et à la formation, avec un laboratoire pleinement opérationnel pour la formation pratique sur la technologie Full Spectrum Profiling™ (FSP®) de Cytek.

L'entreprise a cité une solide performance du secteur des réactifs comme moteur clé et a transféré ses opérations d'entrepôt en interne afin d'améliorer le contrôle de qualité, l'agilité opérationnelle et les délais de réponse dans la région EMEA.

Cytek Biosciences (Nasdaq: CTKB) gab bekannt, dass es seinen europäischen Hauptsitz in eine neue Einrichtung im Life Sciences District von Amsterdam verlegt hat, mit Wirkung zum 15. Oktober 2025. Die Anlage erweitert die europäische Präsenz von Cytek um mehr als 40% und beherbergt Büros, ein vergrößertes Lager und ein dediziertes Kundenservice- und Schulungszentrum mit einem voll funktionsfähigen Labor für praktische Schulungen zur Cytek-Technologie Full Spectrum Profiling™ (FSP®).

Das Unternehmen nannte eine starke Leistung im Bereich Reagenzien als Schlüsselfaktor und hat die Lagerverwaltung intern verlagert, um Qualitätssicherung, operative Flexibilität und Durchlaufzeiten in der EMEA-Region zu verbessern.

Cytek Biosciences (Nasdaq: CTKB) أعلنت أنها نقلت مقرها الأوروبي إلى منشأة جديدة في حي علوم الحياة في أمستردام اعتباراً من 15 أكتوبر 2025. يوسع الموقع حضور Cytek الأوروبي أكثر من 40%، ويتضمن مكاتب ومستودعاً موسّعاً ومركزاً مخصصاً لخدمة العملاء والتدريب مع مختبر وظيفي كامل للتدريب العملي على تكنولوجيا Cytek Full Spectrum Profiling™ (FSP®).

وأشارت الشركة إلى أداء قوي في أعمال المواد الكيميائية كعامل رئيسي، وقد نقلت عمليات المستودع داخلياً لتحسين مراقبة الجودة والمرونة التشغيلية وأزمنة التوريد عبر منطقة أوروبا والشرق الأوسط وأفريقيا (EMEA).

Cytek Biosciences (Nasdaq: CTKB)宣布其欧洲总部已于2025年10月15日起迁至阿姆斯特丹生命科学区的新设施。该地点将 Cytek 的欧洲业务扩展 超过 40%,并设有办公室、扩大的仓库,以及一个专门的客户服务与培训中心,配备用于实际培训 Cytek Full Spectrum Profiling™ (FSP®) 技术的完整实验室。

该公司表示强劲的试剂业务业绩是关键驱动力,并将仓库运营内部化,以提升质量控制、运营敏捷性及跨 EMEA 区域的周转时间。

Positive
  • Footprint expanded by more than 40% in Amsterdam
  • Added dedicated customer service and training center with functional lab
  • Transitioned warehouse operations in-house to improve control and speed
  • Expansion driven by growth in Cytek's reagent business
Negative
  • None.

Insights

Cytek expands EMEA footprint with a larger Amsterdam HQ, hands‑on training center, and insourced reagent warehousing.

Cytek moved its European headquarters to Amsterdam on Oct 15, 2025, increasing the local footprint by more than 40% and adding a dedicated customer service and training center with a functional lab for hands‑on work with Full Spectrum Profiling™ (FSP®) technology. Operationally, the company also transitioned warehouse operations in‑house to support its growing reagent business, which the release cites as a major driver of the expansion.

The business mechanism is straightforward: a larger, integrated EMEA site should shorten fulfillment cycles and concentrate training and customer support, while in‑house warehousing increases control over reagent quality and logistics. Key dependencies and risks include execution of the warehouse transition, actual improvements in turnaround times versus prior third‑party logistics, and the ability of the training center to scale without inflating operating costs. Monitor tangible operational metrics such as order lead times, training throughput, and regional revenue contribution for the reagent line over the next 6–12 months to gauge if the expansion produces measurable commercial benefits.

FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the relocation of its European headquarters to a new facility in Amsterdam’s Life Sciences District. This relocation is an expansion, which reflects Cytek’s commitment to the EMEA region and highlights the company’s ongoing investment in delivering world-class solutions, training, and support to researchers and clinicians worldwide.

The new site houses Cytek European offices and warehouse, which has increased the footprint by more than 40%, with a dedicated customer service and training center. The Training Center offers a fully functional lab environment, enabling researchers to receive hands-on training with Cytek instruments. This ensures scientists can maximize the potential of Cytek’s Full Spectrum Profiling™ (FSP®) technology to unlock high-dimensional data and enable laboratories to achieve more with fewer resources.

The success of Cytek’s reagent business is one of the major drivers of this expansion, signaling its importance to Cytek’s global growth and innovation. As part of a strategic initiative to advance its reagent business, Cytek has transitioned warehouse operations in-house. This strengthens operational oversight, ensuring the highest standards of quality and control across the supply chain. The approach enhances organizational agility, improves operational efficiency, and accelerates turnaround times, delivering a consistent and dependable experience for customers.

“Europe has been a key region in Cytek’s global growth journey, and we are making investments to strengthen our presence there,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. “The new Amsterdam facility expands our capabilities across the EMEA region, enabling us to more efficiently deliver solutions and services that advance scientific understanding, accelerate data-driven decision-making, and foster innovation.”

For more information, please visit https://cytekbio.com/.

About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek’s business strategies, product plans and expectations and market opportunities, including but not limited to, Cytek’s future investment in its EMEA operations; Cytek’s ability to enhance its organizational agility and improve its operational efficiency; and future growth of Cytek’s reagents business. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled “Risk Factors” set forth in Cytek’s Quarterly Report on Form 10-Q filed on August 6, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s as of any date subsequent to the date of this press release.

Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com

Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3c6e0774-3ea5-4bb7-b982-85f249ca52e9


FAQ

What did Cytek (CTKB) announce on October 15, 2025 about its European operations?

Cytek announced relocation of its European headquarters to a new Amsterdam facility, expanding its footprint by more than 40% and adding offices, warehouse, and a training center.

How will Cytek's new Amsterdam facility affect CTKB's reagent operations in EMEA?

The facility supports a strategic push for the reagent business and includes an in-house warehouse to strengthen quality control and speed up turnaround times.

What training capabilities does Cytek's new Amsterdam site provide for CTKB customers?

The site features a dedicated training center with a fully functional lab enabling hands-on training on Cytek's FSP® technology for researchers and clinicians.

Does the Amsterdam expansion change Cytek's customer service in EMEA for CTKB?

Yes. The expanded site consolidates European offices, warehouse, and a customer service center to deliver more consistent and dependable service across EMEA.

Why did Cytek (CTKB) move its European headquarters to Amsterdam in 2025?

Cytek said the move strengthens its EMEA presence, supports reagent-business growth, and improves operational oversight and agility by bringing warehouse operations in-house.
Cytek Biosciences, Inc.

NASDAQ:CTKB

CTKB Rankings

CTKB Latest News

CTKB Latest SEC Filings

CTKB Stock Data

510.17M
115.42M
9.24%
63.36%
4.47%
Medical Devices
Laboratory Analytical Instruments
Link
United States
FREMONT